ChemoCentryx Inc (CCXI.OQ)
26 Jul 2016
* Agreement to commercialize orally administered complement 5a receptor inhibitor CCX168 in Europe and certain other markets
* Receives FDA orphan products development grant for orally administered complement 5A receptor inhibitor CCX168 for treatment of anca-associated vasculitis
* Files for mixed shelf of up to $150 million - SEC filing Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
|Johnson & Johnson (JNJ.N)||$125.37||+0.48|
|GlaxoSmithKline plc (GSK.L)||1,670.00p||+13.00|
|Merck & Co., Inc. (MRK.N)||$58.46||-0.10|
|Abbott Laboratories (ABT.N)||$43.45||+0.04|
|AstraZeneca plc (AZN.L)||4,644.98p||-8.50|
|Pfizer Inc. (PFE.N)||$36.82||+0.04|
|Teva Pharmaceutical Industries Limited (TEVA.TA)||20,840.00₪||-90.00|
|Biogen Inc (BIIB.OQ)||$288.95||+1.60|
|Novartis AG (NOVN.S)||CHF82.50||+0.30|
|Amgen, Inc. (AMGN.OQ)||$167.63||+1.07|
Earnings vs. Estimates
Analyst Research Reports
Provider : Thomson Reuters Stock Report
Provider : ValuEngine, Inc.
ChemoCentryx Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider : Reuters Investment Profile
Provider : Ford Investor Services, Inc.
Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of CHEMOCENTRYX INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.
Provider : Jefferson Research
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.